Dr Rajiv Agarwal Discusses Finerenone, Results of FIDELIO-DKD

Описание к видео Dr Rajiv Agarwal Discusses Finerenone, Results of FIDELIO-DKD

The investigational drug finerenone met its primary endpoint in FIDELIO-DKD of slowing progression of chronic kidney disease (CKD) in patients with type 2 diabetes and CKD, said Rajiv Agarwal, MD, MS, FASN, a professor of medicine at Indiana University School of Medicine and a staff physician at the Veterans Affairs Medical Center in Indianapolis, Indiana.

Комментарии

Информация по комментариям в разработке